Drug Profile
Mitiperstat - AstraZeneca
Alternative Names: AZD-4831Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; University of Cologne
- Class Amines; Cardiotonics; Cardiovascular therapies; Chlorophenols; Heart failure therapies; Organic sulfur compounds; Pyrimidinones; Pyrroles; Small molecules
- Mechanism of Action Peroxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Heart failure
- Phase II Cardiomyopathies; Chronic obstructive pulmonary disease; Non-alcoholic steatohepatitis; Pulmonary hypertension
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Heart-failure(In volunteers) in United Kingdom (PO)
- 24 May 2023 Chemical structure information added
- 16 May 2023 Phase-II clinical trials in Cardiomyopathies in Germany (PO) (EudraCT2022-003797-23)